Real‐world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel.

Autor: Leleu, Xavier, Katodritou, Eirini, Kuehr, Thomas, Terpos, Evangelos, Caers, Jo, Zambello, Renato, Brescianini, Alessandra, Liang, Tony, Wetten, Sally, Badelita, Sorina N.

Publikováno v: EJHaem; Feb2023, Vol. 4 Issue 1, p174-183, 10p

POSTER: MM-372 A Phase III, Two-Stage, Randomized Study of Mezigdomide, Bortezomib, and Dexamethasone (MeziVd) Versus Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Relapsed/Refractory Multiple Myeloma (RRMM): SUCCESSOR-1

Autor: Richardson, Paul G., Badelita, Sorina N., Besemer, Britta, Boudreault, Jean-Samuel, Byun, Ja Min, Cerchione, Claudio, Gatt, Moshe E., Gibbs, Simon, Koroda, Junya, Martinez-Lopez, Joaquín, Min, Chang-Ki, Orlowski, Robert Z., Quach, Hang, Raab, Marc S., Weisel, Katja, Zhou, Xin, Amatangelo, Michael, Wang, Yue, Hwang, Soo Jeong, Emerson, Joshua, Koo, Phillip, Rocci, Alberto, Katz, Jessica

Publikováno v: In Clinical Lymphoma, Myeloma and Leukemia September 2023 23 Supplement 1:S228-S228

P-220: Use of Carfilzomib regimens in patients with Multiple Myeloma refractory to CD38 antibodies: a subgroup analysis from a prospective observational study

Autor: Terpos, Evangelos, Caers, Jo, Badelita, Sorina N, Zambello, Renato, Kuehr, Thomas, Katodritou, Eirini, Brescianini, Alessandra, Liang, Tony, Wetten, Sally, Leleu, Xavier

Publikováno v: In Clinical Lymphoma, Myeloma and Leukemia October 2021 21 Supplement 2:S160-S161

Real-world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel.

Autor: Leleu X; Department of Haematology University Hospital Centre La Miletrie and Inserm Poitiers France., Katodritou E; Department of Haematology Theagenio Cancer Hospital Thessaloniki Greece., Kuehr T; Department of Internal Medicine IV Academic Teaching Hospital Wels-Grieskirchen Wels Austria., Terpos E; Department of Clinical Therapeutics, School of Medicine National and Kapodistrian University of Athens Athens Greece., Caers J; Department of Haematology Liège University Hospital Centre Liège Belgium., Zambello R; Department of Medicine Haematology and Clinical Immunology Branch, University of Padua Padua Italy., Brescianini A; Research and Development Department Amgen (Europe) GmbH Rotkreuz Switzerland., Liang T; Department of Biostatistics Parexel International Taipei Taiwan., Wetten S; Center for Observational Research Amgen Ltd Uxbridge UK., Badelita SN; Department of Hematology Fundeni Clinical Institute Bucharest Romania.

Publikováno v: EJHaem [EJHaem] 2022 Nov 06; Vol. 4 (1), pp. 174-183. Date of Electronic Publication: 2022 Nov 06 (Print Publication: 2023).